Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07541170 Divarasib KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07541170 clinical trial report covering Divarasib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07545395 Armocibart Hemophilia B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545395 clinical trial report covering Armocibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07546500 Azenosertib Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07546500 clinical trial report covering Azenosertib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07546487 Comekibart Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07546487 clinical trial report covering Comekibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07543536 Megestrol Acetate Fatigue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543536 clinical trial report covering Megestrol Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260011 Efgartigimod/Hyaluronidase Graves Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
JPRN-jRCT2071260011 clinical trial report covering Efgartigimod/Hyaluronidase, Phase 3, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07557680 Dexmedetomidine Hydrochloride Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07557680 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07545460 Trastuzumab Brengitecan Recurrent ovarian cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545460 clinical trial report covering Trastuzumab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07544654 Etoposide Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07544654 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07549386 Diacerein Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07549386 clinical trial report covering Diacerein, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07551544 Bacillus Calmette-Guerin(ImmunityBio) Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07551544 clinical trial report covering Bacillus Calmette-Guerin(ImmunityBio), Phase 3, endpoints, sponsor, geography, readout timing and development wh
Latest Hotspot
8 min read
ChiCTR2600124664 Obefazimod Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600124664 clinical trial report covering Obefazimod, Phase 3, endpoints, sponsor, geography, readout timing and development white space.